> ## Content Index > Fetch the complete content index at: https://nexi.fund/llms.txt > Use this file to discover other available public pages before exploring further. # mRNA flu vaccine faces its August 5 verdict: 26.6% efficacy edge, a 9-0 panel vote, and the future of seasonal flu shots - URL: https://nexi.fund/moderna-mrna-flu-vaccine-pdufa-2026/ - Published: 2026-08-03T07:30:34.000Z - Updated: 2026-08-03T07:30:34.000Z - Description: Moderna's mRNA-1010 flu vaccine beat a standard-dose shot by 26.6% relative efficacy, cleared a 9-0 advisory vote, and faces an FDA decision on August 5. What approval would mean for the flu vaccine business. - Author: Nexi.fund Labs - Tags: Biotech & Health, #mode-1, #hook-statistic, #track-A 26.6 percent. That is the relative efficacy edge Moderna's mRNA flu shot showed over a licensed standard-dose vaccine in its pivotal trial. On August 5, the FDA decides whether that is enough to make it the first seasonal mRNA influenza vaccine on the market. ๐ŸŽฏ The Vaccines and Related Biological Products Advisory Committee voted 9-0 that mRNA-1010's benefits outweigh its risks in adults 50 and older, and the decision date is set for August 5. The vaccine beat a standard-dose shot by 26.6% on relative efficacy overall. In adults 65 and older the edge was 27.4%, from a trial of 40,805 people across 11 countries. Approval would reset the flu vaccine business. Egg-based manufacturing, supply lead times, and strain-matching accuracy are all suddenly open questions. Flu vaccine production has worked the same way for seventy years. Grow the virus in eggs, inactivate it, formulate, ship. It works. It is also slow, fragile to strain drift, and hostage to a supply chain that must commit to strains months before the season. 26.6% relative efficacy vs standard shot โ†‘ 27.4% in adults 65+ #### mRNA-1010 relative vaccine efficacy Pivotal Phase 3 trial P304 enrolled 40,805 adults across 11 countries, comparing a single mRNA-1010 dose to a licensed standard-dose flu shot. ยท *VRBPAC briefing document, 2026* ## The road from refusal to a 9-0 vote The path here was not smooth. In February, the FDA refused to file Moderna's application. The Refusal-to-File letter centered on the comparator chosen in the trial: a standard-dose vaccine rather than the high-dose or adjuvanted formulations typically preferred for older adults. Moderna worked through a Type A meeting, revised the submission, and the agency accepted it with a PDUFA date of August 5. The regulatory design that emerged is layered. For adults 50 to 64, Moderna seeks traditional approval, supported by clinical efficacy data. For those 65 and older, the group that carries the bulk of flu mortality, the company seeks accelerated approval, backed by safety, immunogenicity, and relative efficacy data, plus a post-marketing confirmatory study. It is a pragmatic structure. Get the product out before the 2026-2027 season, then prove the hardest claim later. The advisory committee's June vote was unambiguous. Both questions ended 9-0 in favor, with the panel concluding the benefits outweighed the risks. Advisory votes are non-binding, but the agency follows them far more often than not. ## What the data actually shows Relative efficacy of 26.6% means the mRNA vaccine prevented 26.6% more influenza-like illness than a standard-dose comparator. The strain-level breakdown matters for how real this is: 29.6% against A/H1N1, 22.2% against A/H3N2, 29.1% against B/Victoria lineage. This is not a single-strain fluke. The signal is distributed across the main circulating subtypes. The 65-and-older subgroup reported 27.4% rVE, roughly matching the overall population. That is the number that matters most commercially. Older adults are where flu does its damage, where high-dose and adjuvanted vaccines have carved out premium pricing, and where the CDC tracked a 2024-2025 season with over 600,000 hospitalizations. > We believe mRNA-1010 has the potential to provide an important new option for seasonal flu prevention and further demonstrate the versatility of our mRNA platform.โ€” Stรฉphane Bancel, CEO, Moderna The trade-off is on safety. Solicited adverse reactions within seven days were more frequent with mRNA-1010 than with the comparator: injection-site pain, fatigue, headache. The committee weighed this against the efficacy edge and found the balance acceptable. In the 65+ population, where an approval decision must rest on a narrower accelerated-approval base, this reactogenicity profile is the main open question. | Parameter | mRNA-1010 | Standard-dose shot | | --------------------- | ------------------------- | --------------------- | | **Manufacturing** | โœ” cell-free, weeks | โœ— egg-based, months | | **Strain matching** | โœ” precise, late selection | โ— commit months ahead | | **Relative efficacy** | โœ” +26.6% | โ— baseline | | **Reactogenicity** | โ— higher short-term | โœ” milder | Medical Daily / Moderna (Newswire), 2026 ## The business case is not the usual one Here is where this story differs from a typical approval play. Moderna is not modeling revenue from mRNA-1010 in 2026\. The company has said an August approval is late in the flu planning cycle, and it cites the mRESVIA experience: an RSV vaccine approved mid-year in 2024 that generated just $25 million in its first full year, burned by competition and the timing of the season. That honesty matters for anyone reading the decision day as a binary stock event. Historical data on large-cap PDUFA decisions shows a median one-day stock move around 1%. The approval itself is only the beginning of a commercial story that runs through the 2027-2028 season, distribution agreements, ACIP recommendation, and physician adoption. The real prize is platform proof. Flu is a far larger market than RSV. Moderna's CFO has sized the European flu vaccine market at about $1 billion in 2027, against $100 million for RSV. A flu approval would validate the mRNA platform's second major commercial application and set up the combination vaccines, the COVID/flu shot already authorized in Europe as mCOMBRIAX, that are the actual endgame. ### What happens to the market a year from now? ๐Ÿ”ฎ **If approved in August, mRNA-1010 will take meaningful US market share in the 2027-2028 season, not the 2026-2027 one.** Probability: 70% โ€” mid-year approval, conservative company guidance, and the lead time to win ACIP recommendation and distribution slot all push volume to the second season. #### โœ… Arguments for 9-0 advisory vote and a stated agency plan to decide by August 5. Efficacy edge holds across the main circulating strains and in the 65+ subgroup. EU, Canada, and Australia are reviewing in parallel; EU combination vaccine already authorized. **Confirmation criteria:** FDA follows the committee; ACIP recommendation lands before the 2027 season. #### โŒ Arguments against Accelerated approval in 65+ rests on a narrower base; a post-marketing study must still confirm efficacy. Reactogenicity is higher; uptake among a vaccine-skeptical older population is unproven. A mid-year approval repeats the mRESVIA timing failure; incumbents lock seasonal supply early. **Disconfirmation criteria:** FDA delays or conditions the 65+ approval; ACIP defers; first-season volume stays near zero. ### Development scenarios #### ๐ŸŸข Optimistic scenario (30%) Full approval for both age bands, a smooth post-marketing study, and combination vaccine (mRNA-1010 + COVID) clears US regulators quickly. **Implications:** flu becomes a recurring seasonal revenue line and Moderna's commercial floor stops depending on COVID alone. #### ๐ŸŸก Base-case scenario (55%) Approval on schedule with the 50-64 traditional path and 65+ accelerated path; first meaningful US volumes land in the 2027-2028 season. **Implications:** modest 2026 contribution, rising revenue through 2027, and a working proof point for the mRNA platform beyond COVID. #### ๐Ÿ”ด Pessimistic scenario (15%) FDA diverges from the committee, conditions the 65+ approval, or adds a new post-marketing requirement that delays the launch into the next season. **Implications:** the platform story stays one approval behind; competitors' mRNA flu programs gain ground in the interim. ๐Ÿ“Š **Key signals to track** The August 5 FDA decision itself and whether both age bands are approved as proposed. ACIP recommendation and the timing of distribution agreements for the 2027 season. Enrollment and interim readouts of the post-marketing confirmatory study in adults 65+. US regulatory progress of the mCOMBRIAX combination vaccine, already authorized in Europe. [ FDA Advisory Panel Votes on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Scrutiny Comprehensive rundown of the June 18 VRBPAC meeting, the 26.6% relative efficacy reading, the P304 trial scale, and the August 5 decision date. Medical Daily ](https://www.medicaldaily.com/mflusiva-moderna-mrna-flu-vaccine-fda-vrbpac-vote-june-2026-475696?ref=nexi.fund) The primary regulatory source for the efficacy and safety data in this analysis. [ Moderna Announces FDA Advisory Committee Votes Unanimously in Favor of mRNA-1010 Moderna's own announcement of the 9-0 VRBPAC votes, the PDUFA goal date, and the parallel review in the EU, Canada, and Australia. Moderna (Newswire) ](https://www.newswire.com/view/content/moderna-announces-fda-advisory-committee-votes-unanimously-in-favor-of-the?ref=nexi.fund) Independent coverage of the committee vote and the numbers behind it. [ FDA Accepts Revised Application for Moderna's mRNA-1010 Flu Vaccine Context on the February Refusal-to-File letter, the revised submission strategy, and the August 5 decision date. MedTrace ](https://med.agiltrace.com/news/moderna-mrna-1010-fda-review-update?ref=nexi.fund) Background on the regulatory dispute and how Moderna got to a decision date at all.